Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom. (23rd July 2020)

• Record Type: Journal Article
• Authors: Hopewell, Jemma C; Offer, Alison; Haynes, Richard; Bowman, Louise; Li, Jing; Chen, Fang; Bulbulia, Richard; Lathrop, Mark; Baigent, Colin; Landray, Martin J; Collins, Rory; Armitage, Jane; Parish, Sarah
• Is Part Of: European heart journal. Volume 41:Number 35(2020)
• Page Start: 3336
• Page End: 3342
• Publication Date: 2020-07-23
• Subjects: Statins -- Myopathy -- Muscle symptoms -- Risk factors -- SLCO1B1; Cardiology -- Periodicals; Heart -- Diseases -- Periodicals; 616.12005
• DOI: 10.1093/eurheartj/ehaa574
• Languages: English
• ISSNs: 0195-668X

Abstract

Abstract: Aims: Statins are widely used to prevent cardiovascular events, but little is known about the impact of different risk factors for statin-related myopathy or their relevance to reports of other types of muscle symptom. Methods and results: An observational analysis was undertaken of 171 clinically adjudicated cases of myopathy (defined as unexplained muscle pain or weakness with creatine kinase >10× upper limit of normal) and, separately, of 15 208 cases of other muscle symptoms among 58 390 individuals with vascular disease treated with simvastatin for a mean of 3.4 years. Cox proportional hazards models were used to identify independent predictors of myopathy. The rate of myopathy was low: 9 per 10 000 person-years of simvastatin therapy. Independent risk factors for myopathy included: simvastatin dose, ethnicity, sex, age, body mass index, medically treated diabetes, concomitant use of niacin-laropiprant, verapamil, beta-blockers, diltiazem and diuretics. In combination, these risk factors predicted more than a 30-fold risk difference between the top and bottom thirds of a myopathy risk score (hazard ratio : 34.35, 95% CI: 12.73–92.69, P across thirds = 9·1 × 10 −48 ). However, despite the strong association with myopathy, this score was not associated with the other reported muscle symptoms ( P across thirds = 0.93). Likewise, although SLCO1B1 genotype was associated with myopathy, it was not associated with other muscle symptoms. Conclusions: The absolute risk of simvastatin-related myopathy is low, but individuals at higher risk can be identified to help guide patient management. The lack of association of the myopathy risk score with other muscle symptoms reinforces randomized placebo-controlled evidence that statins do not cause the vast majority of reported muscle symptoms.